cropper
update
National Cannabis Newswire
update
  • Home
  • Categories
    • news
    • trends
    • insights
    • industry
    • legalization
    • health
    • culture
    • advocacy
    • Brands
    • New Mexico Dispensaries
    • Arizona Dispensaries
January 11.2026
2 Minutes Read

Why Big Banks Continue to Refuse Cannabis Despite Trump’s Rescheduling Order

Open vault door in industrial setting, representing cannabis industry news access.

Banking On The Cannabis Future: What’s Next?

Despite a monumental executive order from President Donald Trump, aimed at reclassifying marijuana from a Schedule I to a Schedule III substance, major banks in the U.S. remain skeptical and reluctant to provide banking services to the burgeoning cannabis industry. Currently valued at around $32 billion, the cannabis sector is facing significant challenges in gaining financial support, which could grow tenfold if reevaluated with favorable federal policies.

Understanding Trump's Executive Order and Its Implications

Trump's executive order from December 18, 2025, was a strategic move intended to change the narrative around cannabis at a federal level. The order directs the Department of Justice to initiate a reclassification process for marijuana, recognizing its medical potential and aiming to align federal policy with multitude of medical uses being accepted by various states. However, it’s vital to note that this order does not legalize cannabis nor does it eliminate the existing federal tax burdens on cannabis businesses.

Banking Institutions: Progress or Stalemate?

As highlighted in a recent report by The New York Post, big banks such as JP Morgan Chase continue to operate with caution. Reasons for their hesitance stem from fears of potential violations of federal money-laundering rules. “It’s still too early to reconsider our position,” stated a top JP Morgan executive, pointing to the ongoing uncertainty surrounding the final outcomes of Trump’s order.

The Legislative Landscape: What Lies Ahead

Financial experts and industry insiders recognize that the key to moving forward lies with Congress. The SAFER Banking Act, designed to provide protections for banks working with state-legal cannabis businesses, has yet to progress through the Senate, raising concerns about the future of banking in the cannabis sector. Until banking protections are firmly in place, the reluctance among banks to engage with cannabis-related businesses may persist.

Industry Leaders Speak Out

Influential voices within the cannabis sphere are vocal about the disconnect between policy and practice. Marc Cohodes, a noted investor, expressed his frustration with the banking industry’s stance, arguing, “The industry is going to be banked whether they want to or not because Trump wants it to be banked.” With an aligning tone, industry stakeholders are increasingly calling for clearer guidelines from financial institutions, emphasizing the need for banks to recognize the legitimate economic contributions of the cannabis sector.

Conclusion: The Future of Cannabis Banking

While Trump’s executive order marks a significant stride towards welcoming cannabis into the financial fold of America, the pathway remains fraught with challenges. Banks will likely adopt a wait-and-see approach until definitive legislative changes occur. For cannabis businesses, understanding the intricacies of this evolving landscape will be essential to navigating their financial needs. As developments continue, industry watchers will be eager to see how these dynamics unfold and impact the future of cannabis banking.

news

35 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts

Understanding Cannabis Cultivation Risks: Why Facility Design is Key

Update The Hidden Risks of Cannabis Cultivation That You Should Know When discussing the cannabis industry, conversations often gravitate towards the crops—the strains, the pests, and the nutrient needs. However, a pivotal truth is emerging that every cannabis businessman and woman must acknowledge: the most significant risks reside not within the plants themselves, but rather in the facilities and systems designed to cultivate them. This understanding could change not just how businesses operate but also how they achieve long-term profitability. Why Facility Design Matters More Than Ever As cannabis cultivation becomes increasingly sophisticated, operators are facing tighter margins and larger facilities, making the pressure for consistency ever more critical. Many buildings still follow a disjointed model, relying on multiple vendors with separate timelines and fragmented design processes. Consequently, operators can end up with outdated or inefficient systems that impact plant growth, workflow, and overall profitability. In order to thrive, cannabis cultivators must consider an integrated approach to facility design. This is where GrowGeneration has stepped up, introducing the GrowGen BUILD division that offers a comprehensive build platform aiming to reduce risks from conception to commissioning. The Costs of Disconnection When essential aspects of a cultivation operation—like design, procurement, and construction—are handled separately, it creates a disconnect that can lead to reoccurring headaches. As Michael Salaman, co-founder and president of GrowGeneration, opines, 'When design, procurement, and construction are separated, accountability gets diluted.' This can lead to a situation where facilities simply work but fail to achieve optimal productivity and profitability. Enhanced Integration as a Solution The GrowGen BUILD approach empowers operators by ensuring that all stages from initial design to long-term support are coordinated without gaps. This comprehensive service model eliminates blame-shifting between vendors and minimizes surprises that can escalate costs mid-build. By unifying the construction process, operators can mitigate some of the hidden risks associated with cultivation. One advantage of this integration is the streamlined communication it fosters, enabling quicker problem-solving and more efficient management of resources—a vital asset as cultivation facilities expand and grow increasingly complex. Lessons from Other Industries This model of integrated facility design parallels trends seen across various sectors, particularly in tech and manufacturing, where holistic systems lead to higher efficiency and reliability. By employing similar methods in cannabis cultivation, operators can ensure their facilities are equipped to handle rapid growth and increasing demand. Looking Forward: Trends and Predictions The cannabis market is continuously evolving, and as it matures, the need for thoughtful infrastructure will only become more pressing. As tighter regulations and consumer demands rise, cultivation operations must become even more adaptive to remain competitive. The move towards integrated systems signifies a shift toward a future where cannabis cultivators can maximize their output while minimizing the risks associated with poorly designed facilities. In summary, while the heart of every cannabis business lies in the crop, operators must not overlook the importance of robust facility design and integration. For those looking to thrive in this challenging landscape, understanding the risks associated with cultivation facilities may very well be the key to success.

Discovering Hope: How a Single Dose of Psilocybin Can Transform Depression Treatment

Update Transformational Findings: Psilocybin and Depression ReliefImagine feeling clouded by waves of sadness, where every day is a struggle to find joy. Recently, a groundbreaking study from Sweden hints at a remarkable alternative. A single dose of psilocybin, the psychedelic compound found in certain mushrooms, has been shown to induce rapid and long-lasting improvements in those suffering from moderate to severe depression. Conducted by researchers at the esteemed Karolinska Institutet, the research, which was published in JAMA Psychiatry, offers a glimmer of hope in the ongoing battle against mental health disorders.How the Study WorkedThe phase 2 clinical trial involved 35 participants who courageously took part in the adventure of discovery. Half received a 25 mg dose of psilocybin, while the others were given a placebo treatment of niacin. Both groups participated in five psychotherapy sessions to ensure they were supported throughout the experience. Just eight days after treatment, those who took psilocybin experienced noticeable improvements in their mood compared to the control group.The Impact of Findings: What It Means for PatientsDr. Hampus Yngwe, the lead author of this illuminating study, expressed that “this finding implies that psilocybin can be an option to standard treatments when rapid symptom relief is essential.” By week six, over half of those who received psilocybin were in remission, contrasting starkly with only 6% from the placebo group. These statistics are staggering and suggest a shift in how we view depression treatment.Future Implications of Psilocybin ResearchWhile the results flaunt remarkable potential, researchers caution against viewing psilocybin as a cure-all. The study notes that the effects of psilocybin seemed to diminish after a year, and Dr. Yngwe indicated that “repeated treatments may be needed to prevent relapse.” This consideration positions psilocybin as a supplementary tool rather than a definitive solution—an important distinction for patients and providers alike.Cultural Shifts and Therapeutic ExplorationThe potential of psilocybin therapy aligns with a wider trend of interest in psychedelics as treatment options. As state legislatures across the United States grapple with decriminalization, many are exploring these substances for their therapeutic benefits. Nearly 10 million American adults reported microdosing psychedelics in a study by RAND Corporation, illuminating an evolving perspective on mental wellness. As our understanding of these substances grows, so does the importance of cultivated conversations surrounding their use.Final Thoughts: Joining the ConversationAs our society continues to navigate the vast landscape of mental health treatment, it becomes crucial to stay informed about innovative therapies such as psilocybin. This remarkable study opens avenues not just for scientific exploration but also for personal narratives of healing.It’s a time of transformation in mental health approaches, where individuals, communities, and families can come together to explore options that were once considered unconventional. Your voice matters—join the conversation about the therapeutic possibilities of psilocybin and its place in our lives today.

Unpacking Directly Observed Urine Collection Requirements for Truck Drivers

Update The Introduction of Directly Observed Urine Testing in the Trucking Industry In a significant update for truck drivers and federal employees alike, the Department of Transportation will mandate "directly observed" urine drug tests in situations involving oral fluid testing. As of June 10, this change marks a pivotal moment in addressing longstanding challenges related to drug testing within the trucking industry. Understanding the Push for Oral Fluid Testing The campaign to implement oral fluid testing has predominantly been championed by the American Trucking Association (ATA), who argue that its adoption is crucial for maintaining safe roads. Unlike urine tests, saliva tests can detect more recent drug use, thus providing a more accurate assessment of an individual’s immediate impairment. However, despite its approval by the Substance Abuse and Mental Health Services Administration (SAMHSA) back in 2019, the implementation of oral fluid testing has been stalled due to regulatory barriers, primarily the absence of certified laboratories to process these tests. The Challenges of Shy Bladder Syndrome For truck drivers facing paruresis, or "shy bladder syndrome," the anxiety surrounding urine tests can be overwhelming. Traditionally, if a driver cannot provide a urine sample, they must undergo a strenuous process of waiting, which can lead to significant delays. The new DOT regulations aim to address this by allowing collectors to switch to an oral fluid test if the driver is unable to provide urine, thus alleviating the stress and time constraints associated with the current procedures. The Gender Terminology Change: Significance or Controversy? In an additional twist, the DOT rule revises its terminology, replacing "gender" with "sex" to align with President Trump's 2025 executive order. This shift has stirred discussion about the implications it has not only within testing protocols but also in broader conversations around inclusivity and discrimination in workplace environments. Implications for the Trucking Industry With zero laboratories currently certified to conduct oral fluid tests in the U.S., the future of this new testing method remains uncertain. Many in the trucking industry view this as an essential step towards enhancing safety and integrity within the workforce. Yet, the effectiveness and adoption of these tests depend largely on overcoming existing regulatory hurdles that limit their practicality. A Call for Acceptance and Adaptation As the transportation industry adjusts to these changes, adherence to the new drug testing standards will be paramount. Truck drivers and employers alike must stay informed about their rights and responsibilities concerning drug testing. While oral fluid testing introduces practicality, it equally demands compliance with rigorous safety standards that govern all forms of drug testing. Understanding these regulations not only empowers drivers but contributes to a collective effort in fostering safer road environments for everyone. In these evolving times, please take a moment to educate yourself on these regulations and share your thoughts with the community. Advocacy for fair practices can improve workplace conditions across the trucking industry and beyond.

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*